Replies to post #64413 on Biotech Values

[DewDiligence]

>Barr is the king and real innovator of patent challenges.<

Agreed—they basically invented the idea of making the Paragraph-IV challenge a company’s raison d’etre.

>Wonder how many para iv filings they have combined and any overlap.<

The number of challenges is in BRL’s most recent earnings PR. Rather than look it up, tune in to the CC in 30 minutes and you’ll get a more up-to-date figure and probably an overlap figure too.

[DewDiligence]

The combined company will have 200 ANDA’s (worth $120B in branded sales ) and 70 P-IV challenges. US portfolio overlap was characterized as minimal with no actual figure given.

Bruce Downey said Teva had tied to acquire BRL on two prior occasions.

[DewDiligence]

With the benefit of hindsight, I think BRL’s receptiveness to a near-term buyout was evident on the company’s 8-May-2008 CC. Downey was badgered by analysts for the botched quarterly results; instead of retaliating abrasively as he normally does, Downey sounded like Bobby McFerrin singing Don’t Worry Be Happy.


Let’s talk biotech!
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

[DewDiligence]

Biotech soundbite of the month:

Q (analyst on CC): “Where will the $300M of Teva-Barr cost synergies come from?”

A (Bruce Downey, Barr CEO): “A lot of it is me.” (Downey is retiring.)